Literature DB >> 11557492

Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.

J J McSharry1, A McDonough, B Olson, S Hallenberger, J Reefschlaeger, W Bender, G L Drusano.   

Abstract

BAY38-4766 and BAY43-9695 are nonnucleosidic compounds with activities against human cytomegalovirus (HCMV). Two phenotypic assays were used to determine the drug susceptibilities of 36 HCMV clinical isolates to the BAY compounds and ganciclovir. Using either assay, both BAY compounds at a concentration of approximately 1 microM inhibited the replication of all 36 HCMV clinical isolates, including 11 ganciclovir-resistant clinical isolates, by 50%.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11557492      PMCID： PMC90754          DOI： 10.1128/AAC.45.10.2925-2927.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.

Authors:  S C Stanat; J E Reardon; A Erice; M C Jordan; W L Drew; K K Biron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 2.  Recent advances in the therapy and prevention of CMV infections.

Authors:  W G Nichols; M Boeckh
Journal:  J Clin Virol       Date:  2000-02       Impact factor: 3.168

Review 3.  Ganciclovir.

Authors:  C S Crumpacker
Journal:  N Engl J Med       Date:  1996-09-05       Impact factor: 91.245

Review 4.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

5.  Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates.

Authors:  J M McSharry; N S Lurain; G L Drusano; A Landay; J Manischewitz; M Nokta; M O'Gorman; H M Shapiro; A Weinberg; P Reichelderfer; C Crumpacker
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

6.  Inhibition of murine cytomegalovirus and human cytomegalovirus by a novel non-nucleosidic compound in vivo.

Authors:  O Weber; W Bender; P Eckenberg; S Goldmann; M Haerter; S Hallenberger; K Henninger; J Reefschläger; J Trappe; A Witt-Laido; H Ruebsamen-Waigmann
Journal:  Antiviral Res       Date:  2001-03       Impact factor: 5.970

Review 7.  Antiviral drug susceptibility assays: going with the flow.

Authors:  J J McSharry
Journal:  Antiviral Res       Date:  1999-08       Impact factor: 5.970

8.  A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.

Authors:  A G Palestine; M A Polis; M D De Smet; B F Baird; J Falloon; J A Kovacs; R T Davey; J J Zurlo; K M Zunich; M Davis
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

9.  Anticytomegaloviral activity and safety of cidofovir in patients with human immunodeficiency virus infection and cytomegalovirus viruria.

Authors:  M A Polis; K M Spooner; B F Baird; J F Manischewitz; H S Jaffe; P E Fisher; J Falloon; R T Davey; J A Kovacs; R E Walker
Journal:  Antimicrob Agents Chemother       Date:  1995-04       Impact factor: 5.191

10.  Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56.

Authors:  P M Krosky; M R Underwood; S R Turk; K W Feng; R K Jain; R G Ptak; A C Westerman; K K Biron; L B Townsend; J C Drach
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103
View more
  11 in total

1.  Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients.

Authors:  Raymund R Razonable; Carlos V Paya; Thomas F Smith
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 2.  Current and emerging antivirals for the treatment of cytomegalovirus (CMV) retinitis: an update on recent patents.

Authors:  Aswani D Vadlapudi; Ramya K Vadlapatla; Ashim K Mitra
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2012-04

Review 3.  Human cytomegalovirus resistance to antiviral drugs.

Authors:  C Gilbert; G Boivin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

Review 4.  The search for new therapies for human cytomegalovirus infections.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Virus Res       Date:  2010-11-21       Impact factor: 3.303

Review 5.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

6.  Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

Authors:  J J McSharry; A McDonough; B Olson; C Talarico; M Davis; K K Biron
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

7.  The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.

Authors:  Mark R Schleiss; David I Bernstein; Michael A McVoy; Greg Stroup; Fernando Bravo; Blaine Creasy; Alistair McGregor; Kristin Henninger; Sabine Hallenberger
Journal:  Antiviral Res       Date:  2005-01       Impact factor: 5.970

Review 8.  Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements.

Authors:  Nancy Perrottet; Laurent A Decosterd; Pascal Meylan; Manuel Pascual; Jerome Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

9.  Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

Authors:  James J McSharry; Ann C McDonough; Betty A Olson; George L Drusano
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

10.  Antiviral Drugs Against Herpesviruses.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.